AbbVie Inc
재무 요약
Finnhub /stock/metric · 연간 기준 · 캐시 6h▸ Finnhub /stock/profile2 · 캐시 24h · 모든 수치 API 원값 (RICHMAP 가공·추정 없음)
관련 뉴스
Finnhub /company-news · 최근 14일 · 캐시 30minABBV Jumps on Deepening Immunology Portfolio With $10.9B APGE Buyout
AbbVie shares jump after its $10.9B Apogee deal adds late-stage eczema and respiratory candidates, deepening its immunology pipeline.
원문 보기 ↗ YahooAre Biosimilars Becoming a Key Pillar of Amgen's Growth Story?
AMGN's biosimilars business is driving growth, with new launches and a deep pipeline helping offset patent losses in key branded drugs.
원문 보기 ↗ YahooCompany News for Jun 23, 2026
Companies in The News Are: APGE, ABBV, DLR, META, SNDK
원문 보기 ↗ YahooAbbVie Secures EU Approval for Skyrizi in Pediatric Plaque Psoriasis (ABBV)
European Commission Expands Skyrizi Label to Younger PatientsAbbVie (NYSE:ABBV) has received approval from the European Commission to use Skyrizi (risankizumab) in children and adolescents aged six ye…
원문 보기 ↗ YahooShould You Buy Or Sell AbbVie Stock At $230?
The drugmaker has successfully replaced its former blockbuster, but buying into that victory today means paying a steep premium for its next act.
원문 보기 ↗ YahooPiper Sandler Reiterates Overweight on AbbVie, Maintains $298 Price Target
Piper Sandler analyst David Amsellem reiterates AbbVie (NYSE:ABBV) with a Overweight and maintains $298 price target.
원문 보기 ↗ BenzingaAllergan Aesthetics receives approval for Boey® (trenibotulinumtoxinE) in Canada, the first and only rapid-onset, short-duration neurotoxin for the temporary improvement of frown lines in adult patients
Today, Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announced Health Canada has approved Boey® (trenibotulinumtoxinE) for the temporary improvement in the appearance of moderate to severe line…
원문 보기 ↗ Yahoo3 Biotech Takeover Targets Wall Street Is Watching After the Apogee Deal
Big pharma’s appetite for clinical-stage biotech is back. The pending acquisition of Apogee Therapeutics by AbbVie (NYSE: ABBV), targeting an atopic dermatitis and immunology developer, has reignited …
원문 보기 ↗ YahooCanaccord Genuity Maintains Buy on AbbVie, Raises Price Target to $273
Canaccord Genuity analyst Gary Nachman maintains AbbVie (NYSE:ABBV) with a Buy and raises the price target from $265 to $273.
원문 보기 ↗ BenzingaEnanta Pharmaceuticals’ Partner AbbVie Receives European Commission Approval of MAVIRET® (Glecaprevir/Pibrentasvir) for People with Acute Hepatitis C Virus
WATERTOWN, Mass., June 23, 2026--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological di…
원문 보기 ↗ YahooAbbVie Announces European Commission Approval of MAVIRET® (Glecaprevir/Pibrentasvir) for People with Acute Hepatitis C Virus Infection
AbbVie (NYSE: ABBV) today announced that the European Commission approved MAVIRET® (glecaprevir/pibrentasvir), an oral pangenotypic direct-acting antiviral (DAA) therapy for the treatment of acute hep…
원문 보기 ↗ YahooAbbVie Announces European Commission Approval of SKYRIZI® (risankizumab) for the Treatment of Pediatric Patients with Moderate to Severe Plaque Psoriasis
AbbVie (NYSE: ABBV) today announced that the European Commission (EC) has approved SKYRIZI® (risankizumab) for the treatment of children and adolescents six years of age and older with moderate to sev…
원문 보기 ↗ Yahoo내 성향 트레이더로 도전
주어는 당신의 성향이지 이 종목이 아닙니다. 객관식 3개로 트레이더를 만들고, 6시간 동안 30분마다 가상 매매하는 걸 관전합니다. 하루 1번, 외부 개입 0.
트레이더 성향 설정
객관식만 · 주관식 0 · 생성 후 변경 불가
본 페이지는 정보 제공 목적의 종목 정보 색인이며, 투자 권유·자문·중개가 아닙니다. RICHMAP은 증권사·금융투자업자가 아닙니다. 시세·재무·뉴스는 외부 데이터 소스(Finnhub 등)의 정보로 실시간성·정확성을 보증하지 않습니다. 모든 수치는 API 원값으로 RICHMAP의 가공·추정이 없으며, 조회 실패 시 "데이터 없음"으로 명시됩니다. 투자 판단과 그 결과 책임은 본인에게 있으며, 실제 거래는 정식 인가 증권사를 통해 본인 판단하에 진행하시기 바랍니다.